

1 **GDP Release from the Open Conformation of G α Requires Allosteric Signaling from the**
2 **Agonist Bound Human β_2 Adrenergic Receptor**

3 **Vikash Kumar^{1#}, Hannah Hoag^{2#}, Safaa Sader², Nicolas Scorese², Haiguang Liu^{1*} and**
4 **Chun Wu^{2*}**

5 ¹ Complex Systems Division, Beijing Computational Science Research Center, Haidian district,
6 Beijing, 100193 China

7 ² College of Science and Mathematics, Rowan University, Glassboro, NJ 08028 USA

8 [#] Both authors have contributed equally

9 *To whom correspondence should be addressed: wuc@rowan.edu or hgliu@csrc.ac.cn

10 **Abstract**

11 G-protein-coupled receptors (GPCRs) transmit signals into the cell in response to ligand binding
12 at its extracellular domain, which is characterized by coupling of agonist induced receptor
13 conformational change to guanine nucleotide (GDP) exchange with GTP on a heterotrimeric
14 ($\alpha\beta\gamma$) guanine nucleotide-binding protein (G-protein), leading to the activation of the G-protein.
15 The signal transduction mechanisms have been widely researched *in vivo* and *in silico*. However,
16 coordinated communication from stimulating ligands to the bound GDP still remains elusive. In
17 the present study, we used microsecond (μ S) molecular dynamic (MD) simulations to directly
18 probe the communication from beta2 adrenergic receptor (β_2 AR) with an agonist or an antagonist
19 or no ligand to GDP bound to the open conformation of $G\alpha$ protein. MM-GBSA calculation
20 results indicated either agonist or antagonist destabilized the binding between the receptor and
21 the G-protein, but agonist cause a higher level destabilization than antagonist. This is consistent
22 with the role of agonist in the activation of G-protein. Interestingly, while GDP remained bound
23 with the $G\alpha$ -protein for the two inactive systems (antagonist bound and apo form), GDP
24 dissociated from the open conformation of $G\alpha$ protein for the agonist activated system. Data
25 obtained from MD simulations indicated that the receptor and the $G\alpha$ subunit play a big role in
26 coordinated communication and nucleotide exchange. Based on residue interaction network
27 analysis, we observed that engagement of agonist bound β_2 AR with $\alpha 5$ helix of $G\alpha$ is essential
28 for the GDP release and the residues in phosphate-binding loop (P-loop), $\alpha 1$ helix, and $\alpha 5$ helix
29 play very important roles in the GDP release. The insights on GPCR/G-protein communication
30 will facilitate the rational design of agonists and antagonists that target both active and inactive
31 GPCR binding pockets, leading to more precise drugs.

33

34 **Introduction**

35 Guanine nucleotide-binding proteins, known as G-proteins, are a family of proteins that act as
36 molecular switches inside the cell. Receptors on the cell surface coupled to heterotrimeric G-
37 proteins are known as G-protein coupled receptors (GPCRs). The GPCR protein family is one of
38 the largest membrane protein families and is encoded by over 800 genes in the human genome ¹.
39 Targeting the GPCR family can produce therapeutic agents that reduce neurological disorders,
40 asthma, chronic obstructive pulmonary disease, cancer, and inflammatory diseases ². GPCR
41 signal transduction mechanisms have been widely researched, including pathways and response ³.
42 Although ligand-GPCR interactions and GPCR-trimeric protein interactions have been
43 extensively studied ², coordinated communication from stimulating ligands to their effector GDP
44 still remains elusive. GPCR conformational changes and subsequent nucleotide exchange is not
45 well understood. Understanding GPCR conformational changes and G-protein stimulation can be
46 very beneficial in developing novel drugs for various diseases.

47 The heterotrimeric ($\alpha\beta\gamma$) G-protein, in its inactive form, is bound to guanosine diphosphate
48 (GDP). Upon activation of the GPCR by an agonist, the G-protein undergoes a significant
49 conformational change, leading to that the GDP is released and guanosine triphosphate (GTP)
50 spontaneously binds to the vacated binding site. When GDP is released and the G-protein is
51 bound to GTP, the G-protein dissociates into a $\text{G}\alpha$ subunit and a $\text{G}\beta\gamma$ complex. The $\text{G}\alpha$ subunit is
52 evolutionarily related to the Ras family of proteins. Based on sequences and functions, $\text{G}\alpha$
53 proteins have been divided into four main families (**Figure S1**), $\text{G}\alpha_s$, $\text{G}\alpha_q/11$, $\text{G}\alpha_i/\text{G}\alpha_o$ and
54 $\text{G}\alpha_{12}/\text{G}\alpha_{13}$ ⁴. All $\text{G}\alpha$ subunit contains two domains (**Figure S2**), the Ras domain ($\text{G}\alpha\text{Ras}$) and the

55 alpha-helical domain (G α AH)⁴. The G α Ras domain contains the nucleotide binding site and the
56 G α AH domain is responsible for domain separation by moving away from G α Ras⁵.

57 The β_2 AR (**Figure 1**) is often used as a model system to study the GPCR family. Chung et al.,
58 used the β_2 adrenergic receptor-G protein complex to examine nucleotide exchange⁶. They
59 speculated that the release of GDP is initialized by the interactions between intracellular loop 2
60 (ICL2) of β_2 AR and α N helix of G α S and coupled to the subsequent structural changes in the
61 highly conserved peptide-binding loop (P-loop). Dror et al., addressed important questions about
62 domain separation and GDP release using β_2 AR⁷. They carried out atomic-level MD simulations
63 of heterotrimeric G-proteins with and without bound GPCR. Using the crystal structure of the
64 β_2 AR- G-protein complex (nucleotide-free), 66 simulations were performed using lengths of up
65 to 50 μ s each⁷. They also completed simulations of a GDP-bound G-protein without β_2 AR. In
66 these simulations, the G α subunit and G α AH domains separated from one another. This open
67 conformation of the G α subunit resembles the nucleotide-free β_2 AR-G protein complex
68 conformation. Although domain separation occurred, GDP remained bound throughout the
69 simulations. Even removal of the G α AH did not promote GDP leaving G α Ras domain in
70 simulation. Separation occurs spontaneously even when GPCR is not bound to the heterotrimeric
71 G protein. Above findings by Dror et al., suggest that domain separation is necessary but not
72 sufficient for GDP release. Furthermore, a weakening of nucleotide-Ras domain contacts is also
73 required. The shift up of α 5 helix, induced by an activated β_2 AR, favors GDP detachment and
74 nucleotide exchange through conformational changes at the G α Ras domain⁷. Computational
75 studies of thromboxane A2 receptor (TXA₂R)-Gq complex revealed that contacts between C-
76 terminus of α 5 and receptor are major players in the receptor catalyzed motion of the α H domain
77 and eventually the release of GDP⁸. Recent computational study suggests that the rate limiting

78 step for GDP release involves translation or tilting of $\alpha 5$ helix ⁹. We refer these models as a “ $\alpha 5$ -
79 centered” model for the GDP release. Despite these progresses, there is little information on how
80 binding of $G\alpha$ to an activated β_2 AR weakens the interaction between GDP and Ras domain,
81 promoting GDP release. For example, because $\alpha 4$ and αN are also in contact with IntraCellular
82 Loop 2 and 3 (ICL2 and ICL3) of the receptor, respectively, do they also play some roles in the
83 conformational change at the $G\alpha$ Ras domain that weakens the GDP affinity? What are the major
84 communication pathways from the agonist to GDP? What are the critical residues in these
85 pathways? Can those key residues explain the mutagenesis experimental data? What is the
86 receptor and G-protein response when the agonist is changed to an antagonist or no ligand? In
87 present study, we have investigated the communication between agonist or antagonist bound
88 β_2 AR and GDP bound $G\alpha$ protein. The simulation results highlighted the important regions in
89 $G\alpha$ which are responsible for GDP release. Findings from the present study provide insight on
90 GPCR-G-protein activation and GDP release mechanism.

91 **Materials and Methods**

92

93 **Homology modeling of human $\beta 2$ -adrenergic- $G\alpha\beta\gamma$ complex**

94 Rasmussen et al. has determined a crystal structure of the chimeric $\beta 2$ -Adrenergic receptor in
95 complex with a G_s -protein complex ⁵. In the crystal structure (PDB ID 3SN6), human $\beta 2$ -
96 adrenergic receptor (30-341) has two missing regions (176-178 and 240-264) which belong to a
97 part of extracellular loop2 (ECL2) and intracellular loop3 (ICL3) respectively. Crystal structure
98 has $G\alpha$ and $G\gamma$ from *Bos taurus* (domestic cattle) and $G\beta$ from *Rattus norvegicus* (brown rat).
99 Using the pre-aligned crystal structure in membrane from the OPM web server¹⁰ as a template,
100 we applied homology modeling procedure to complete the short missing region of β_2 AR (172-

101 178) and to construct a full model of human β_2 AR-G α β γ complex. The template also contains
102 agonist BI-167107, which was incorporated into the modeled complex. To get the binding pose
103 of an antagonist (alprenolol), we superimposed the homology model of β_2 AR with another
104 crystal structure of β_2 AR in complex with alprenolol (PDB: 3NYA)¹¹, and thus the crystal pose
105 of alprenolol was adopted.

106 **Molecular docking of GDP**

107 Protein structures were prepared using Maestro protein preparation wizard (Schrödinger Release
108 2019-4: Maestro, Schrödinger, LLC, New York, NY, 2019). First, the charge state of
109 preprocessed complexes was optimized at pH=7. Second, a restrained minimization was
110 performed to relax the protein structures using OPLS3 force field. The prepared complexes were
111 used to generate docking grid files. Site identified by the site detection tool was specified as the
112 binding site for the GDP. The prepared GDP was docked into the grid using Glide XP scoring
113 function with default procedures and parameters (Schrödinger Release 2019-4: Glide,
114 Schrödinger, LLC, New York, NY, 2019). The receptor grid was generated using Van der Waals
115 scaling factor of 1 and partial charge cutoff 0.25. The ligand docking was performed using a
116 ligand-centered grid using OPLS3 force field. The obtained complex from the Glide XP docking
117 was further subjected to an induced fit docking (IFD) to obtain the final complex. To confirm the
118 GDP binding site in our homology model we superimposed the closed G α subunit containing
119 GDP (PDB: 1GOT)¹² with our human G α subunit containing the docked GDP.

120 **System setup for all-atom Molecular Dynamics Simulations**

121 Each of the three pre-aligned complexes (the agonist, antagonist and apo complex systems) was
122 placed in a membrane consisting of phosphatidylcholines (POPC). Then, each system was

123 solvated in an orthorhombic water box with a 10 Å water buffer and neutralized by Na^+ ions.
124 Additional Na^+ and Cl^- ions were added to reach 0.15 M NaCl salt concentration. The total
125 number of atoms for each system was roughly ~139,000 and the system size with membrane in
126 x, y, z directions was ~100.1 Å, ~102.2 Å and ~133.4 Å, respectively. POPC is the most
127 common lipid in animal cells ¹³, and POPC lipid bilayer is prototypical model and wildly used in
128 MD simulations of membrane proteins ^{14, 15}, some of which were along with OPLS-AA
129 (optimized potential for liquid simulations-all atom) force field ^{16, 17}. Simple point-charge (SPC)
130 ¹⁸ water model was used, and OPLS3 force field ¹⁹ was used to model protein, lipids, ligand and
131 ions.

132 Using Desmond module (Schrödinger Release 2019-4: Desmond Molecular Dynamics System,
133 D. E. Shaw Research, New York, NY, 2019.), the system was first relaxed using the default
134 relaxation protocol for membrane proteins. This relaxation protocol consists of eight stages: 1).
135 Minimization with restraints on solute heavy atoms; 2) Minimization without any restraints; 3).
136 Simulation with heating from 0 K to 300 K, H_2O barrier and gradual restraining; 4). Simulation
137 under the NPT ensemble (constant number of particles, constant pressure of 1 bar and constant
138 temperature of 300 K) with H_2O barrier and with heavy atoms restrained; 5) Simulation under
139 the NPT ensemble with equilibration of solvent and lipids; 6). Simulation under the NPT
140 ensemble with protein heavy atoms annealing from 10.0 kcal/mol to 2.0 kcal/mol; 7). Simulation
141 under the NPT ensemble with $\text{C}\alpha$ atoms restrained at 2 kcal/mol; and 8) Simulation for 1.5 ns
142 under the NPT ensemble with no restraints. After the relaxation, each system was subject to a
143 3000.0 ns simulation for the NPT ensemble using the default protocol. As a control, a second set
144 of simulation trajectories (each is 1000.0 ns) were generated. Temperature was controlled using
145 the Nosé-Hoover chain coupling scheme with a coupling constant of 1.0 ps. Pressure was

146 controlled using the Martyna-Tuckerman-Klein chain coupling scheme with a coupling constant
147 of 2.0 ps. M-SHAKE was applied to constrain all bonds connecting hydrogen atoms, enabling a
148 2.0 fs time step in the simulations. The k-space Gaussian split Ewald method was used to treat
149 long-range electrostatic interactions under periodic boundary conditions (charge grid spacing of
150 ~1.0 Å, and direct sum tolerance of 10^{-9}). The cutoff distance for short-range non-bonded
151 interactions was 9 Å, with the long-range van der Waals interactions based on a uniform density
152 approximation. To reduce the computation, non-bonded forces were calculated using an r-
153 RESPA integrator where the short-range forces were updated every step and the long range
154 forces were updated every three steps. The trajectories were saved at 40.0 ps intervals for
155 analysis. The SCHRODINGER's Simulation Interactions Diagram (SID) tool and VMD ²⁰ were
156 used to analyze the simulation data.

157 **Residues interaction network analysis**

158 For creation of network map, C α atoms were considered as nodes. Edges were drawn if nodes
159 were within cutoff distance of 4.5 Å for at least 75% of the trajectory. The early study has shown
160 that the effect of the cutoff parameter on the network properties is minor when the cutoff
161 distance ~ 4.5 Å ²¹. CARMA tool ²² was used to calculate cross correlation map of C α atoms of
162 complexes over 1.2 μ s trajectory. The edge distances d_{ij} are derived from the pairwise
163 correlations (C_{ij}) between C α atoms ²¹. Where d_{ij} defines the probability of information transfer
164 across a given edge.

165
$$d_{ij} = -\log(|C_{ij}|)$$

166
$$C_{ij} = \frac{\langle \Delta \vec{r}_i(t) \cdot \Delta \vec{r}_j(t) \rangle}{(\Delta \vec{r}_i(t)^2 \cdot \Delta \vec{r}_j(t)^2)^{1/2}}$$

167 Where $\Delta \vec{r}_i(t) = \vec{r}_i(t) - \langle \vec{r}_i(t) \rangle$ and $\vec{r}_i(t)$ is the position of the atom corresponding to
168 i^{th} node ²¹. C_{ij} is the probability of transfer information across a given edge. Networks were
169 visualized using the “NetworkView” module ²³ of the VMD. After selection of start and sink
170 nodes, “subopt” program was used to calculate optimal and suboptimal paths between them. In
171 addition to weighting networks based on the correlated motion in the simulation trajectory, the
172 networks may also be weighted based on the strength on interactions within a single structure as
173 demonstrated by Vishveshwara and coworkers^{24 25}. Dynamic network models have been
174 effectively used to decipher allosteric and communication pathways in transmembrane proteins²⁶.
175 Using a dynamic network model, Schneider et al. have successfully identified different pathways
176 leading to biased and unbiased activation of the μ -Opioid Receptor²⁷. Jiang et al. have also
177 successfully used a network model to elucidate the dynamic and allosteric properties of three
178 GPCR homodimers ²⁸.

179 **Binding energy calculations**


180 Molecular Mechanism-General Born Surface Area (MM-GBSA)²⁹ binding energies were
181 calculated on the frames in the last 200 ns of the combined trajectories for each system. OPLS3
182 force field, VSGB 2.0 solvation model ³⁰ and the default Prime procedure was used for the MM-
183 GBSA calculation. The default procedure consists of three steps: Receptor alone (minimization),
184 Ligand alone (minimization), Receptor-ligand complex (minimization). The total binding free
185 energy equation is: $\Delta G_{\text{bind}} = E_{\text{complex (minimized)}} - (E_{\text{ligand(minimized)}} + E_{\text{receptor(minimized)}})$. There are
186 three components analyzed: $E_{\text{Electrostatics}} (H_{\text{bond}} + E_{\text{coulomb}} + E_{\text{GB_solvation}})$, $E_{\text{vdW}} (E_{\text{vdW}} + E_{\pi-\pi \text{ stacking}} + E_{\text{self-}}\text{contact})$, and $E_{\text{lipophilic}}$.

188 **Results and discussions**


189 **Agonist and antagonist bound human β 2AR-G α -protein complexes**

190 We used crystal structure of chimeric human β 2AR-Gprotein complex (PDB ID 3SN6)
191 containing agonist BI-167107 as the template for homology modeling. Sequence alignment
192 showed that different types of G α share significant homology with each other (**Figure S1**). The
193 chimeric human crystal structure is shown in **Figure S2**. To confirm the GDP binding site in the
194 homology model, we aligned the closed G α subunit containing GDP (PDB: 1GOT) with human
195 G α subunit containing the docked GDP (**Figure S3 and S4**). Compared to the co-crystallized
196 conformation in the closed form of G α , the G α with docked GDP has a similar conformation to
197 that in the open form. Structural alignment of closed and open forms of G α showed that the RAS
198 domain does not undergo large conformational change during GDP release. Secondary structure
199 elements of RAS domain are shown in **Figure S5**. 3D coordinates of antagonist (alprenolol) was
200 transferred to the homology model after superposing the modelled human β 2AR with another
201 crystal structure containing alprenolol (PDB: 3NYA). Binding pocket residues interacting with
202 BI-167107, alprenolol and GDP are shown in **Figure 1**. The full complexes in three states
203 (agonist bound, antagonist bound, and apo) are summarized in **Figure 2**.

204



207 **Figure 1.** Initial conformations of (A) agonist (green), (B) antagonist (green) and (C) GDP (pink)
 208 in their corresponding binding pocket in β₂AR (for agonist and antagonist) and Gαq (for GDP).



212 **Figure 2.** β₂AR-G-protein complexes with GDP (tan colour and surface representation) and (A)
 213 Agonist (magenta colour and surface representation) (B) Antagonist (magenta colour and surface
 214 representation) and (C) without agonist or antagonist (apo system). Cartoon representation of
 215 β₂AR, Gαq, Gβ and Gγ are shown in orange, green, blue and yellow colours respectively. In **S1**
 216 and **S2 Tables**, residues of β₂AR and Gαq are listed according to the GPCR naming scheme and
 217 common Gα naming scheme, respectively.

218 **Effect of agonist and antagonist on human β_2 AR-G α q complex**

219 Backbone root mean square deviation (RMSD) analyses showed that all systems have reached to
220 the steady state with the progress of MD simulation. The RMSD of different components of the
221 β_2 AR-G-protein complexes are shown in **Figure S6 and S7**. In the agonist bound system
222 (**Figure S6A and S7A**), there is a clear gap in RMSD values between the components containing
223 the G α subunit and the components that do not, thus forming two groups. The full complex, the
224 G-protein and the G α subunit all have RMSD values of about 5 Å or higher, while the individual
225 subunits (β_2 AR, G β , G γ) and the G β - γ complex have RMSD values between 2-4 Å. The same
226 separation is seen in the antagonist complex (**Figure S6B and S7B**). The 3 μ s trajectory of apo
227 complex (**Figure S6C**) does not have a visible separation between groups, and the G γ subunit is
228 comparative in RMSD values to the G α subunit. However, the second trajectory of apo complex
229 (**Figure S7C**) depicted a small separation between groups. In agonist bound system, larger
230 separation denotes destabilization of the β_2 AR-G α β γ interface.

231 Co-RMSF analysis (**Figure S8 and S9**) of β_2 AR showed that at ECL2 there is slightly more
232 fluctuation in the agonist bound β_2 AR. At ICL3, the fluctuation in the agonist bound β_2 AR is
233 nearly doubled compared to the case of antagonist bound β_2 AR. ICL3 is the largest ICL and the
234 loop in closest contact with the G-protein. Residues in the ICL3 make contacts with α 5 helix of
235 G α ³¹. The α 5 helix is the last helix of the Ras domain and it is in direct contact with the β_2 AR. In
236 **Figure S8B**, there are visibly larger fluctuations in the antagonist complex, as compared to the
237 agonist complex in the alpha helical domain of the G α subunit. In second trajectory (**Figure**
238 **S9B**), alpha helical domain in the agonist bound system showed larger fluctuations compared to
239 antagonist bound and apo systems. However, in the first trajectory, Ras domain for the agonist
240 G α subunit there is more fluctuation at α 4, α 5 and β 6. In **Figure S8C**, there is a similar level of

241 fluctuations in the G β subunit for the agonist as compared to the antagonist. In **Figure S8D**,
242 compared to agonist and antagonist complexes, there is larger fluctuation in the G γ subunit for
243 the apo complex, but similar fluctuation in the second helix for both subunits. In second
244 trajectories (**Figure S9C and S9D**), we observed that G β and G γ subunits of agonist complex
245 showed higher fluctuation than antagonist bound and apo complexes. After comparison of RMSF
246 profiles of both trajectories for the three systems we see that while the β_2 AR and the G β subunit
247 have smaller fluctuation (1.95 \AA and 1.66 \AA respectively), the G α subunit and the N-terminal part
248 of the G γ subunit have much larger fluctuation (2.33 \AA and 4.89 \AA respectively), suggesting the
249 latter parts are the response regions where the larger conformation change can be induced.
250 The ligand- β_2 AR contacts are summarized in **Table 1**. The contact histograms of agonist and
251 antagonist are also shown in **Figure S10**. Asp 113^{3.32}, Phe 193^{E2}, Phe 290^{6.52} and Asn 312^{7.39} are
252 in contact with both the agonist and antagonist for at least 30.0% of the 3 μ s simulations. The
253 agonist and antagonist interact with residues mainly from TM 3, 5, 6 and 7.

254

255

256 **Table 1: Ligand-Receptor Contacts**

Agonist	Antagonist
W109 ^{3.28}	D113 ^{3.32}
D113 ^{3.32}	F193 ^{E2}
F193 ^{E2}	F290 ^{6.52}
S203 ^{5.42}	N312 ^{7.39}
S207 ^{5.46}	V114 ^{3.33*}
F290 ^{6.52}	F289 ^{6.51*}
N293 ^{6.55}	Y308 ^{7.35*}
N312 ^{7.39}	I309 ^{7.36*}


257 *Not in contact more than 30.0% of simulation time

258

259

260 We analyzed the effects of agonist and antagonist on molecular switches of β_2 AR. Ionic lock
 261 between Asp130^{3.49} and Arg131^{3.50} was found to be broken in both systems. Even in the absence
 262 of agonist or antagonist, ionic lock was broken. On the other hand, the transmission switch was
 263 intact in all three systems. Only tyrosine toggle switch was affected by the binding of agonist
 264 uniquely. We observed toggle of side chain of tyrosine in the agonist bound β_2 AR. The torsion
 265 angle analysis was carried out for the chi1 and chi2 angles within Y326^{7.53} of the tyrosine toggle
 266 switch (**Figure S11 and S12**). The chi1 analysis shows a relatively flat plot for the agonist bound
 267 and apo complexes (**Figure S11A and C**). The antagonist complex showed change (**Figure**
 268 **S11B**) early in the simulation trajectory (~100 ns), but then remained stable for the remainder of
 269 the trajectory. Chi2 analysis (**Figure S12**) shows much larger changes within all three systems.
 270 The agonist complex (**Figure S12A and D**) is the only system which showed similar rotameric
 271 toggle of Y326^{7.53}. In the first trajectory of antagonist system (**Figure S12B**), chi2 of Y326^{7.53}
 272 took various values between -180 and 180 degrees. However, in second trajectory of antagonist
 273 system (**Figure S12E**), chi2 showed values between 60 to 120 degrees. In both first and second
 274 trajectories of apo system (**Figure S12C and F**), Y326 appeared to take various values between -

275 180 to 180 degrees. We observed that Y326^{7.53} interacts with the Arg131^{3.50} in all three
276 complexes.



278 **Figure 3:** RMSD of different regions of G_{aq}. Agonist bound system (A) antagonist bound system
279 (B) and apo system (C).

280 We also investigated the effects of agonist and antagonist on different regions of G_{aq} subunit.
281 RMSD analysis for the G α -N-terminal, β 1, P-loop, α 1, α G, β 6- α 5 loop and α 5 helix is shown in
282 **Figure 3**. In agonist bound and apo systems (**Figure 3A and C**), RMSD values for the α N helix
283 values were below 7 Å. However, in antagonist bound system (**Figure 3B**), α N helix showed
284 deviation greater than 7 Å. In the agonist bound system (**Figure 3A**), α G showed higher RMSD
285 than antagonist bound and apo system. We measured the distances between center-of-mass of the
286 α 5 helix and GDP, and between the center-of-mass of the β 6- α 5 loop and GDP (**Figure S13**).
287 The apo complex remains constant for both the α 5 helix and the β 6- α 5 loop with values of
288 approximately 25 Å and 15 Å, respectively. The antagonist bound complex showed minor
289 changes throughout the analysis for both measurements. The α 5 helix distance starts around 30-
290 31 Å and ends at approximately 27 Å. The decrease is gradual with little to no fluctuation during
291 the simulation. The β 6- α 5 loop distance shows similar results for the antagonist bound system.
292 The distance stays between 18-22 Å for the first 600 ns then decreases to about 13-15 Å for the

293 remainder of the simulation. The $\beta 6-\alpha 5$ distance in agonist bound system begins at
294 approximately 11 Å then quickly begins to fluctuate between 12-22 Å until the simulation
295 reaches approximately 800 ns. At 800 ns the distance was about 26 Å then reduced to 9 Å. At
296 950 ns, the distance increased again to 23 Å before GDP begins to move out of the binding
297 pocket. GDP appears to leave the binding pocket completely at about 1170 ns where the distance
298 jumps to above 40 Å.

299

300 **MM-GBSA binding energies indicate that the agonist destabilizes the GPCR-G-protein**
301 **complex**

302 MM-GBSA energy calculations were carried out at three interfaces of the β_2 AR-G-protein
303 complex, as described in the method section. These results summarized in **Table 2** indicate that
304 the agonist binds more favorable to the β_2 AR binding pocket than the antagonist by -60 kcal/mol.
305 However, at the β_2 AR-G-protein interface, the free energy binding is much more favorable for
306 the antagonist system at -237 kcal/mol as compared to the agonist system at -163 kcal/mol. The
307 apo complex was even more favorable at -249 kcal/mol for the β_2 AR-G-protein. At the G-
308 protein-GDP interface, the agonist has the weakest binding at -22 kcal/mol. The apo and
309 antagonist complexes have free binding energies of -48 kcal/mol and -32 kcal/mol respectively.

310 The MM-GBSA binding energies (**Table 2**) clearly demonstrate destabilization through agonist
311 binding at two interfaces of the β_2 AR-G-protein complex. This is consistent with our initial
312 results from the simulation trajectories. Agonist destabilization at both the β_2 AR-G-protein and
313 G-protein-GDP interface may likely correlate to the downstream effects of G-protein signaling.
314 GDP leaves the agonist complex in the simulation indicating that destabilization is necessary for
315 nucleotide exchange. The G-protein dissociates from the β_2 AR after nucleotide exchange is

316 complete, indicating that destabilization at this interface is also necessary. Both the agonist (BI-
317 167107) and the antagonist (alprenolol) bind to the same binding pocket in the β_2 AR. The MM-
318 GBSA values indicate the agonist binds more favorably to the β_2 AR. Ligand RMSD shows
319 similar deviations within the β_2 AR binding pocket and the ligands have similar key contact
320 residues (**Table 1**).


321 **Table 2: MM/GBSA (kcal/mol) Comparisons**

	No Ligand	Antagonist	Agonist
Ligand - Receptor		-125.0 ± 5.0	-185.0 ± 17.0
Receptor - G-protein	-249.0 ± 18.0	-237.0 ± 15.0	-163.0 ± 8.0
GDP - G-protein	-48.0 ± 4.0	-32.0 ± 8.0	-22.0 ± 8.0

322

323 **Conformation of GDP in the nucleotide binding pocket of G α**

324 The conformational change of GDP in all three complexes starts at approximately the same level,
325 as shown in **Figure 4 and S14**. GDP in the agonist complex (**Figure 4A and S14A**) begins to
326 deviate significantly from the initial state and this deviation within the binding pocket indicates
327 that conformational change is necessary for GDP dissociation. Interestingly, GDP assumed
328 conformation (**Figure 5A**) similar to the co-crystallized conformation in the closed form of G α
329 (**Figure 5B**). GDP deviation drastically changes at about 1250 ns and reaches a value of 70-75
330 Å (**Fig 4A**). The deviation stays consistent for GDP in both the apo (**Figure 4E and S14E**) and
331 antagonist bound (**Figure 4C and S14C**) complexes. MD simulation shows GDP dissociation
332 from the agonist G α subunit only (**Figure 4A and S14A**).




333

334 **Figure 4.** RMSD (left) and distances (right) between atoms of GDP and atoms of residues within
 335 binding pocket in Gαq. Agonist bound system (A and B) antagonist bound system (C and D) and
 336 apo system (E and F).

337 In the crystal structure (PDB ID: 1GOT) of heterotrimeric complex of G α -G α chimera with G β
 338 and G γ ¹², GDP makes extensive interactions with P-loop and α 1 helix residues. In human G α ,
 339 Ser50^{G.s1h1.5}, Gly51^{G.s1h1.6}, Lys52^{G.H1.1} and Ser53^{G.H1.2} are the important residues which hold the α
 340 and β phosphates. In this crystal structure, α H domain of G α is in contact with GDP.

341 For GDP release, α H domain must move away from the nucleotide binding site. Recent study by
 342 Dror et al., has revealed that GDP remains bounded to the $\text{G}\alpha$ -Ras domain even after separation
 343 of α H domain ⁷. In our study we also observed that GDP remains bounded to the open
 344 conformation of $\text{G}\alpha$ in both antagonist (**Figure 4C and S13C**) and apo (**Figure 4E and S14E**)
 345 systems.



346

347 **Figure 5.** Conformation of GDP (orange) in (A) Crystal structure of G_t - G_i chimera (PDB
 348 ID:1GOT) and (B) Human $\text{G}\alpha_q$ coupled to agonist bound human $\beta_2\text{AR}$ (structure extracted at $t =$
 349 100 ns). H-bonds are shown in dashed black line.

350 In the case of agonist bound system (**Figure 4A-B and S14A-B**), GDP does not stay longer in
 351 the nucleotide binding pocket of G -alpha subunit. We observed that guanine ring of GDP rotates
 352 and makes interaction with $\text{Asn}274^{\text{G.S5.7}}$ side chain and $\text{Asp}277^{\text{G.HG.2}}$. Initially, β phosphate
 353 shows interaction with $\text{Ser}50^{\text{G.s1h1.5}}$, $\text{Gly}51^{\text{G.s1h1.6}}$, $\text{Lys}52^{\text{G.H1.1}}$ and $\text{Ser}53^{\text{G.H1.2}}$ but after 150 ns, β
 354 phosphate loses interaction with the side chain of $\text{Lys}52^{\text{G.H1.1}}$ (**Figure 4B**). Concomitant with the
 355 loss of $\text{Lys}52^{\text{G.H1.1}}$ - β -phosphate interaction, another residue $\text{Lys}57^{\text{G.H1.6}}$ in the α 1-helix appeared
 356 to make interaction with β phosphate. $\text{Lys}57^{\text{G.H1.6}}$ also showed interaction with α -phosphate.
 357 GDP does not show any persistent interaction with α 5- β 6 loop. The GDP in the agonist complex

358 is not in contact with any residues for at least 30.0% of the simulation time (**Table 3**). We
 359 observed similar interaction profile of GDP in the second trajectory (**Figure S14B**).

360 MD simulations allowed the relaxation of the GDP conformation in the nucleotide binding
 361 pocket, leading to the establishment of interactions with Asn274^{G.S5.7}, Lys275^{G.s5hg.1} and
 362 Asp277^{G.HG.2}, which are also present in the template crystal structure.




Figure 6: Histograms showing dynamic interaction profile of GDP in (A) Antagonist bound system) and (B) apo system.

366 In the antagonist-bound system (**Figure 4C-D and S14C-D**), GDP showed strong interaction
 367 with P-loop residues. Only α and β phosphates interact with the residues of P-loop and α 1-helix.
 368 The GDP- G α subunit contacts are listed in **Table 3**. The 2D interaction diagrams and contact
 369 histograms for GDP in the antagonist and apo complexes are shown in **Figure 6**. Ser 50^{G.s1h1.5},
 370 Gly51^{G.s1h1.6}, Lys52^{G.H1.1} and Ser 53^{G.H1.2} are in contact with GDP in both the antagonist bound
 371 complex for at least 30.0% of the simulation time. Interaction of α and β phosphates of GDP
 372 with the side chain of Lys57^{G.H1.6} was absent.

373 In the apo system (**Figure 4E-F and S14E-F**), guanine ring rotates while making interaction
 374 with side chain of Asp277^{G,HG,2}. Rotation of guanine ring leads to the establishment of H-bond
 375 between N7 and side chain of Asn274^{G,S5,7}. Initially, β phosphate of GDP makes strong
 376 interactions with the residues in the P-loop and α 1-helix. Ser50^{G,s1h1,5}, Gly51^{G,s1h1,6}, Lys52^{G,H1,1}
 377 and Ser53^{G,H1,2} are the important residues which hold the β phosphate. Interactions with side
 378 chain of Asn274^{G,S5,7} and Asp277^{G,HG,2} persist throughout simulation. Apart from H-bonds and
 379 electrostatic interaction, GDP makes van der Waal interaction with the side chain of Lys275^{G,S5,8}.
 380 GDP does not show any interactions with α 5- β 6 loop and side chain of Lys57^{G,H1,6}. In the apo
 381 complex GDP is also in contact with Thr54^{G,H1,3}, Asn 274^{G,S5,7} and Asn277^{G,HG,2} for at least
 382 30.0% of the simulation time.

383 **Table 3. GDP-G α q Contacts.**

Agonist	Antagonist	No Ligand
S53 ^{α1*}	E49 ^{α1}	S50 ^{α1}
K57 ^{α1*}	S50 ^{α1}	G51 ^{α1}
K274 ^{αG*}	G51 ^{α1}	K52 ^{α1}
D277 ^{αG*}	K52 ^{α1}	S53 ^{α1}
	S53 ^{α1}	T54 ^{α1}
		N274 ^{αG}
		D277 ^{αG}

384 *Not in contact more than 30.0% of simulation time

385
 386 Trajectory images (**Figure S15**) show locations of GDP throughout the simulation for each
 387 system. GDP movement within the antagonist bound and apo systems, G α subunits is minimal in
 388 these images. GDP movement within the agonist G α subunit is visible. GDP appears to make
 389 conformational changes before being expelled from the G α subunit. The GDP conformational
 390 changes within the binding pocket are indicative of coordinated communication between the
 391 activated GPCR and the G-protein. The agonist activated GPCR induces a change with the


392 G α Ras binding pocket that induces a change in GDP binding. This is in agreement with the
393 previous finding that opening of the G α domains alone is not sufficient for nucleotide exchange.
394 We also observed GDP re-attachment to the G β subunit which appears to be the artefact due to
395 the limitations set by the simulation box.

396 **Release of GDP needs strong coordinated communication between agonist bound β 2-
397 adrenergic receptor and G α**

398 At the β 2AR-G-protein interface, there are several regions of G α which can receive signals from
399 the β 2AR. However, in order to eject GDP from the nucleotide binding pocket, all signals must
400 converge to the nucleotide binding pocket of G α . Previous studies regarding GPCR-G-protein
401 complex activation and nucleotide exchange provide valuable information about the nucleotide
402 release. As stated earlier, Chung et. al. completed research to better understand the molecular
403 workings of G-protein activation through peptide amide hydrogen-deuterium exchange mass
404 spectrometry ⁶. They determined that P-loop stabilization is a key determinant of GDP binding
405 affinity. Dror et al., used MD simulations to analyze the G α subunit domains and nucleotide
406 release ⁷. They determined that domain separation is necessary but not sufficient for the GDP
407 departure. GPCR's facilitate a conformational change within the Ras domain to weaken
408 nucleotide affinity. Dror et al., used a previous mutagenesis study to confirm this conclusion
409 about domain separation. This mutagenesis study suggested that weakening interactions between
410 the β 6- α 5 loop and GDP facilitates nucleotide release to a greater extent than increasing domain
411 separation ³².

412 Network analysis of all three systems (**Table S3-4, Figure 7 and Figure S15-23**) gave important
413 clues about the information transfer from ligand binding site to GTP binding site. Compared to

414 antagonist bound system (**Figure 7B**), communication between β_2 AR and P-loop is stronger in
 415 the presence of agonist (**Figure 7A**). In case of agonist bound system, optimal path length
 416 between Asp113^{3.32} of β_2 AR and Ser50^{G.s1h1.5} of G α was 225. For antagonist (**Figure 7B**) and
 417 apo (**Figure 7C**) systems, optimal path lengths were 462 and 232 respectively. We observed that
 418 optimal paths of agonist bound and apo systems were similar. We found Arg60^{G.H1.9} as a critical
 419 node in both 3 μ s and 1 μ s trajectories for the agonist system.



420


421 **Figure 7:** Optimal paths connecting the start and end points in the agonist bound system (A)
 422 antagonist bound system (B) and apo system (C). β_2 AR and G α q are shown in white and yellow
 423 color respectively.

424 Network analysis suggested the critical role of α 5 helix in the GDP release. It is a well-
 425 established fact the α 5 helix interacts with the GPCR. However, little information is available on
 426 the role of α 5 helix in the GDP release. We found that signal for the GDP release starts at the
 427 Asp113^{3.32} residue located on TM3 of β_2 AR and reaches to P-loop via α 5 helix of G α subunit.

428 Optimal paths involve residues of TM3 and G α -RAS domain. Recent study has suggested that
429 TM3 plays very important role in the G-protein recruitment ³³. It has been reported that
430 conformational change in α 5 helix affects the nucleotide biding region by affecting β 6- α 5 loop
431 and α G helix ^{8,9}. Asn274^{G.S5.7} and Asp277^{G.HG.2} are located on β 5 strand α G helix respectively.
432 Loop connecting the α G to β 5 harbours Lys275^{G.s5hg.1}. β 5 strand forms parallel sheet with β 6. In
433 present study, residues of β 6- α 5 loop do not interact directly with GDP. Glu335^{G.H5.2} in the α 5
434 makes salt bridge with Arg60^{G.H1.9} residue located on α 1. Arg60^{G.H1.9} is in close proximity to the
435 linker (L1) region. L1 connects the Ras domain to the α H domain and it is followed by the α 1
436 helix and P-loop. Hence any change in the α 5 may affect the P-loop. Another possible way for
437 the signal transfer is via N-terminal. Intracellular loop 2 (ICL2) of the β 2 adrenergic receptor
438 makes interaction with the residues of α N and α N- β 1 loop. However, in optimal paths we did not
439 see any residue belonging to α N and α N- β 1 loop. In the network analysis, we observed that
440 residues in the β 4 (L229^{G.S4.5}) and β 5 (I270^{G.S5.3} and F272^{G.S5.5}) strands are part of the optimal
441 path between agonist binding site and GDP binding site. Both I270^{G.S5.3} and F272^{G.S5.5} are
442 conserved across different families of G α (Figure S1). Recent study suggests the role of β 1- β 3
443 strands in GDP release ⁹ but role of β 4- β 5 has not been reported.

444 We also analyzed the important interactions at β ₂AR-G α interface (**Figure 8**). C-terminal region
445 of α 5-helix of G α interacts with the transmembrane region of the β ₂-AR. We observed
446 interaction between Arg131^{3.50} of β ₂-AR and Tyr356^{G.H5.23} of G α at side chain level. Distance
447 between center of mass of Arg131^{3.50} and Tyr356^{G.H5.23} was calculated for all three systems. In
448 agonist bound system (**Figure 8A and B**), compared to the antagonist bound system (**Figure 8C**
449 **and D**) and apo system (**Figure 8E and F**), average distance was relatively smaller (8.16 \AA for
450 agonist, 9.43 \AA for antagonist and 9.92 \AA for no ligand) and more stable till 2 μ s. In the 1 μ s

451 trajectory (**Figure S24**), we observed a similar trend (8.44 Å for agonist, 8.87 Å for antagonist
452 and 9.34 Å for no ligand). It is clear that in the agonist bound system α 5 helix of $G\alpha$ interacts
453 strongly with TM3 of β_2 -AR. Previous study⁵ has reported about the interaction between
454 Arg131^{3.50} and Tyr356^{G.H5.23} but its role in the GDP release has not been discussed. In a study by
455 Goetz et al., 2011³⁴, compared to inverse agonist and antagonist, agonist bound β_2 AR complex
456 exhibited stable binding with $G\alpha$ CT. In other study³⁵, crystal structure of agonist bound β_2 AR
457 with $G\alpha$ CT showed that $G\alpha$ CT assumed different conformation in which R389 and E392 of $G\alpha$
458 exhibited interactions with Asp130^{3.49} and Arg131^{3.50} of β_2 AR. Authors have hypothesized that
459 above interactions may initiate GDP release. In $G\alpha$ q, R389^{G_{aq}} and E392^{G_{aq}} are replaced by
460 K354^{G_{aq}} and N357^{G_{aq}} respectively. In our study we observed that $G\alpha$ CT maintained the similar
461 conformation as reported in the crystal structure of β_2 AR-G protein and Y356 of $G\alpha$ q exhibited
462 interaction with Arg131. It is possible that the association of G-protein with activated β_2 AR may
463 involve several intermediate steps.



464

465 **Figure 8.** Distances between center of mass of Arg131^{3.50} (β_2 AR) and Tyr356^{G.H5.23} (G α q) in
 466 agonist bound system (A) antagonist bound system (C) and apo system (E). Snapshot taken at
 467 1 μ s showing interaction between Arg131^{3.50} and Tyr356^{G.H5.23} in agonist bound system (B)
 468 antagonist bound system (D) and apo system (F).

469

470 **Effect of agonist and antagonist on interdomain distance in the open conformation of G α**

471 As discussed previously, separation of α H domain and Ras domain is important for the GDP
472 release. In the crystal structure of β_2 AR-G_{as}-protein (PDB ID:3SN6), interdomain distance is
473 62.68 \AA (distance between C α atoms of Ala161^{H.HE.6} and Glu299^{G.hgh4.9}). We observed that
474 interdomain distance does not change significantly when G α q is coupled to either agonist or
475 antagonist bound β_2 AR. In the apo system, average interdomain distance was 65.13 \AA (**Table 4**).
476 In the presence of agonist and antagonist, average interdomain distances were 61.75 \AA and
477 67.43 \AA respectively (**Table 4**). We see that average interdomain distance in the agonist bound
478 system stays very close to the distance observed in the crystal structure. However, we think that
479 longer simulation time is required to see the effect of ligands on interdomain distance between
480 α H and RAS domains.

481
482

483 **Table 4. Average interdomain distance between α H and Ras domains. Distance was**
484 **calculated between C α atoms of Glu143^{H.HE.6} and Glu281^{G.hgh4.9}.**

485


System	Average interdomain distance (\AA)
Agonist	61.75 \pm 2.00
Antagonist	67.47 \pm 1.98
Apo	65.13 \pm 1.51

486

487 **Residues in the α 1 helix of the G α control the release of GDP**

488 It is important to discuss the relative contributions of different types of interactions which keep
489 the GDP in the pocket. Residues in the nucleotide binding pocket which interact with either α or
490 β phosphate or both have greater impact on the GDP conformation and position. In the agonist
491 system, we observed that interaction of β -phosphate of GDP with the side chain of Lys52^{G.H1.1}

492 disappears before 200 ns and this loss of interaction leads to the establishment of salt bridge
 493 between Lys52^{G.H1.1} and Asp205^{G.S3.7} (**Figure 9A**), also observed in the second trajectory of
 494 agonist system (**Figure S25A**).



495
 496 **Figure 9.** Breakage and formation of salt bridges near nucleotide binding pocket in the G α q. (A)
 497 Agonist bound system (B) antagonist bound system and (C) apo system. All residues belong to
 498 G α q.


499 After losing the interaction with Lys52^{G.H1.1} side chain, Lys57^{G.H1.6} sidechain initialized the
 500 interaction with the α phosphate, subsequently led to the movement of α phosphate group
 501 towards the side chain of Lys57^{G.H1.6}. Interaction of GDP with Lys57^{G.H1.6} was only present in

502 the agonist bound system. 1 μ s trajectory of agonist bound system (**Figure S9B**) also
503 substantiated the role of Lys57^{G.H1.1} in GDP release. Lys52^{G.H1.1}-Asp205^{G.S3.7} salt bridge was not
504 present in two trajectories of antagonist system (**Figure 9B and S25B**) and one trajectory of apo
505 system (**Figure 9C**). However, in the other trajectory of apo system (**Figure S25C**), Lys52^{G.H1.1}-
506 Asp205^{G.S3.7} salt bridge was present and interactions of β -phosphate with Lys52^{G.H1.1} and
507 residues of P-loop were absent. According to Chung et al.,⁶ P-loop stabilization and β -phosphate
508 coordination are important for GDP(and GTP) affinity. In a computational study by Louet et
509 al.,³⁹ it was found that in heterotrimeric G-proteins, GDP release preferentially occurs on the
510 phosphate side. Another important interaction which may play key role in the GDP release is the
511 breakage and formation of salt bridges involving Arg60^{G.H1.9}. We observed that Arg60^{G.H1.9}-
512 Asp195^{G.S2.7} salt bridge is only present in the $\text{G}\alpha\text{q}$ of agonist bound system (**Figure 9A and**
513 **S25A**). Recent study by Sun et al., suggests the role of $\alpha 1$ helix in GDP release⁹. Mutational
514 studies have shown that mutations of Lys52^{G.H1.1}, Lys57^{G.H1.6} and Arg60^{G.H1.9} affect the stability
515 of $\text{G}\alpha$ -GDP complex³¹. Arg60^{G.H1.9}Cys mutation has been reported to cause autosomal dominant
516 hypo-parathyroidism by affecting the H-domain opening and GDP release³¹. We found that
517 Arg60^{G.H1.9} acts as a critical node in the network map of agonist bound system (**Table S3 and**
518 **S4**).

519 **Summary of the agonist induced GDP release from the open conformation of $\text{G}\alpha$.** Before
520 release of first crystal structure of agonist bound GPCR- $\text{G}\alpha\beta\gamma$ complex (PDB ID: 3SN6),
521 different models were proposed to explain the GDP release⁸. One of the models known as
522 “lever-arm” suggests that $\text{G}\beta\gamma$ complex acts as lever which tilts the $\text{G}\alpha$, leading to opening of the
523 nucleotide binding pocket^{36,37}. Other model known as “gear-shift” suggests that GPCR uses N-
524 terminus of $\text{G}\alpha$ to shift the $\text{G}\beta\gamma$ towards the $\text{G}\alpha$ ³⁸. Shifting of $\text{G}\beta\gamma$ towards $\text{G}\alpha$ induces

525 conformational change in α 5 helix. Above models became less significant after the release of
526 crystal structure of agonist bound GPCR-G α β γ complex which shows engagement of α 5 helix
527 with the GPCR. Crystal structure shows that GPCR bound G α is in open conformation. Previous
528 “ α 5-centered” models have not addressed the GDP release from the open conformation of G α in
529 the presence of agonist bound β ₂AR, considering only β ₂AR free nucleotide bound G α ⁹ or
530 nucleotide free β ₂AR-G α ⁷. Therefore we carried out multiple microseconds MD simulations to
531 provide a structural view of allosteric communication between agonist binding pocket of β ₂AR
532 and nucleotide bound to the open conformation of G α . MD simulations revealed that binding of
533 agonist is necessary for the GDP release for the first time. In two independent simulations, GDP
534 moves out of the nucleotide binding pocket. Interestingly, in both trajectories, GDP leaves the
535 nucleotide binding pocket in similar fashion. We observed that exit route of GDP involves α 1
536 and α 5 helices. It is noteworthy that in both agonist bound and apo systems, GDP undergoes
537 conformational change in similar fashion. Based on the MD simulation results, we have
538 summarized the information transfer from agonist binding site to GDP in the pictorial form
539 (**Figure 10 and 11**). Figure 10, shows that the GDP release is an outcome of coordination of
540 multiple residues belonging to different regions of β ₂AR and G α . From the β ₂AR side, we found
541 that TM3 helix plays critical role in the signal transfer to the open conformation of G α subunit.
542 We found that the interaction between Arg131^{3.50} of DRY motif and Y356^{G.H5.23} of α 5, acts as
543 a bridge to link the information flow from receptor to the G α . In particular, in the presence of
544 agonist, Arg131^{3.50} of DRY motif forms strong cation- π interaction with Y356^{G.H5.23} of α 5. In G α i,
545 mutation of residue at equivalent position (G.H5.23) affect the stability of GPCR-G α i complex³¹.
546 Mutations in the C-terminal of α i have been reported to affect the G-protein activation⁴⁰. Recent
547 computational study has also shown that displacement of α 5 helix induces GDP release⁹. Our

548 findings strongly support the dominant role of $\alpha 5$ helix in the release of GDP from the open
 549 conformation of G_{α} . Furthermore, our communication network model appears to provide more
 550 complete picture than the early models including the “ $\alpha 5$ -centered models”. Encouragingly, key
 551 residues and secondary elements identified in our communication network are consistent with the
 552 experimental studies. We observed that agonist induced perturbations in the β_2 AR travel to G_{α}
 553 and eventually abolish the electrostatic interactions of α and β phosphates of GDP within the
 554 nucleotide binding pocket (**Figure 4**). Overall our study suggests that agonist binding to the
 555 β_2 AR is prerequisite for the GDP release (**Figure 10 and 11**).



556


557 **Figure 10.** Strong communication pathway involves red solid arrows and light green boxes.
 558 Important residues involved in the allosteric communication have been highlighted.

559

560

561

562



563

564 **Figure 11.** GDP release mechanism. (A) GDP tightly bound to closed conformation of G α in the
 565 receptor free G $\alpha\beta\gamma$ complex (PDB 1GOT) (B) GDP bound G $\alpha\beta\gamma$ complex interacts with activated
 566 receptor and α 5 docks into the intracellular cavity of β_2 AR. α 5 is pulled towards the receptor and
 567 subsequently β 6- α 5 loop moves away from the guanine ring of GDP. Open conformation of G α
 568 gets stabilized. Movement of α H domain also affects P-loop and α 1. (C) Allosteric signal passes
 569 through α 5 and propagates to the P loop and α 1 and conformational change in P loop and α 1
 570 leads to the release of GDP (PDB 3SN6).

571

572

573

574 **Conclusions**

575 MD simulations demonstrate the effects of an agonist and an antagonist on G-protein activation
576 and therefore nucleotide exchange. MM-GBSA analysis shows the destabilization of the GPCR-
577 G-protein complex due to agonist binding. The binding of antagonist has a smaller
578 destabilization effect. This destabilization is likely to be the preparation for GDP release and G-
579 protein dissociation. While the tyrosine toggle switch (NPXXY) appears to be activated in the
580 agonist complex, we argue that molecular switches might not crucial for this β_2 AR-G-protein
581 activation. The RMSD and RMSF analyses revealed important conformational changes within
582 the GPCR and G-protein. The largest changes within the receptor occur at the ECL2 and ICL3.
583 The $G\alpha$ subunit plays the largest role in G-protein activation and GDP release. Residue
584 interaction network analysis revealed the coordinated communication paths between
585 agonist/antagonist binding pocket and GDP binding pocket. We found that $\alpha 5$ helix receives the
586 signal from the agonist bound β_2 AR and transmit to the other parts of $G\alpha$. In the agonist bound
587 system, strong interaction between TM3 and C-terminus of $\alpha 5$ helix promotes the GDP release.
588 Conserved residues of $\alpha 1$ -helix responsible for the release of GDP were also identified for the
589 experimental validation. Present study will be helpful in understanding the mechanism of $G\alpha$
590 activation and nucleotide exchange.

591 **Acknowledgements**

592 C.W acknowledges the support by Rowan SEED grant and the National Science Foundation
593 under Grants NSF ACI-1429467/RUI-1904797, and XSEDE MCB 170088. The Anton2 machine
594 at the Pittsburgh Supercomputing Center (PSCA17017P) was generously made available by D. E.
595 Shaw Research. The grants from National Natural Science Foundation of China (11575021,
596 U1530402) to H.L. are also acknowledged.

597

598 **Supporting information available:**

599 Supporting information contains 4 tables (Table S1 to S4) and 25 figures (Figure S1 to S25).

600 **References:**

- 601 1. Zhang, D.; Zhao, Q.; Wu, B., Structural Studies of G Protein-Coupled Receptors. *Mol. Cells* **2015**, *38*, 836-42.
- 602 2. Hauser, A. S.; Attwood, M. M.; Rask-Andersen, M.; Schioth, H. B.; Gloriam, D. E., Trends in GPCR drug
603 discovery: new agents, targets and indications. *Nat. Rev. Drug Discov.* **2017**, *16*, 829-842.
- 604 3. Hilger, D.; Masureel, M.; Kobilka, B. K., Structure and dynamics of GPCR signaling complexes. *Nat. Struct.
605 Mol. Biol.* **2018**, *25*, 4-12.
- 606 4. Jastrzebska, B., GPCR: G protein complexes--the fundamental signaling assembly. *Amino Acids* **2013**, *45*,
607 1303-14.
- 608 5. Rasmussen, S. G. F.; DeVree, B. T.; Zou, Y. Z.; Kruse, A. C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P.
609 S.; Pardon, E.; Calinski, D.; Mathiesen, J. M.; Shah, S. T. A.; Lyons, J. A.; Caffrey, M.; Gellman, S. H.; Steyaert, J.;
610 Skiniotis, G.; Weis, W. I.; Sunahara, R. K.; Kobilka, B. K., Crystal structure of the beta(2) adrenergic receptor-Gs
611 protein complex. *Nature* **2011**, *477*, 549-U311.
- 612 6. Chung, K. Y.; Rasmussen, S. G.; Liu, T.; Li, S.; DeVree, B. T.; Chae, P. S.; Calinski, D.; Kobilka, B. K.; Woods, V.
613 L., Jr.; Sunahara, R. K., Conformational changes in the G protein Gs induced by the beta2 adrenergic receptor.
614 *Nature* **2011**, *477*, 611-5.
- 615 7. Dror, R. O.; Mildorf, T. J.; Hilger, D.; Manglik, A.; Borhani, D. W.; Arlow, D. H.; Philippsen, A.; Villanueva, N.;
616 Yang, Z. Y.; Lerch, M. T.; Hubbell, W. L.; Kobilka, B. K.; Sunahara, R. K.; Shaw, D. E., Structural basis for nucleotide
617 exchange in heterotrimeric G proteins. *Science* **2015**, *348*, 1361-1365.
- 618 8. Raimondi, F.; Seeber, M.; De Benedetti, P. G.; Fanelli, F., Mechanisms of inter- and intramolecular
619 communication in GPCRs and G proteins. *J. Am. Chem. Soc.* **2008**, *130*, 4310-4325.
- 620 9. Sun, X.; Singh, S.; Blumer, K. J.; Bowman, G. R., Simulation of spontaneous G protein activation reveals a
621 new intermediate driving GDP unbinding. *Elife* **2018**, *7*.
- 622 10. Lomize, M. A.; Pogozheva, I. D.; Joo, H.; Mosberg, H. I.; Lomize, A. L., OPM database and PPM web server:
623 resources for positioning of proteins in membranes. *Nucleic Acids Res.* **2011**, *40*, D370-D376.
- 624 11. Wacker, D.; Fenalti, G.; Brown, M. A.; Katritch, V.; Abagyan, R.; Cherezov, V.; Stevens, R. C., Conserved
625 Binding Mode of Human β 2 Adrenergic Receptor Inverse Agonists and Antagonist Revealed by X-ray
626 Crystallography. *J. Am. Chem. Soc.* **2010**, *132*, 11443-11445.
- 627 12. Lambright, D. G.; Sondek, J.; Bohm, A.; Skiba, N. P.; Hamm, H. E.; Sigler, P. B., The 2.0 Å crystal structure of
628 a heterotrimeric G protein. *Nature* **1996**, *379*, 311-319.

- 629 13. Jambeck, J. P.; Lyubartsev, A. P., An Extension and Further Validation of an All-Atomistic Force Field for
630 Biological Membranes. *J Chem Theory Comput* **2012**, *8*, 2938-48.
- 631 14. Pan, D. S.; Wang, W.; Liu, N. S.; Yang, Q. J.; Zhang, K.; Zhu, J. Z.; Shan, S.; Li, Z. B.; Ning, Z. Q.; Huang, L. Q.;
632 Lu, X. P., Chiglitzar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and
633 Phosphorylation Inhibition of PPAR gamma. *Ppar Research* **2017**.
- 634 15. Ebadi, A.; Dastan, D.; Azami, M.; Karimi, A.; Razzaghi-Asl, N., Molecular Modeling of Human CCR2
635 Receptor within POPC Lipid Bilayer. *Structural Chemistry* **2016**, *28*, 849-857.
- 636 16. Khatami, M. H.; Saika-Voivod, I.; Booth, V., All-atom molecular dynamics simulations of lung surfactant
637 protein B: Structural features of SP-B promote lipid reorganization. *Biochim. Biophys. Acta, Biomembr.* **2016**, *1858*,
638 3082-3092.
- 639 17. Khatami, M. H.; Bromberek, M.; Saika-Voivod, I.; Booth, V., Molecular dynamics simulations of histidine-
640 containing cod antimicrobial peptide paralogs in self-assembled bilayers. *Biochim. Biophys. Acta, Biomembr.* **2014**,
641 1838, 2778-2787.
- 642 18. Mark, P.; Nilsson, L., Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K. *J. Phys.*
643 *Chem. A* **2001**, *105*, 9954-9960.
- 644 19. Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J. Y.; Wang, L.; Lupyan, D.; Dahlgren, M. K.;
645 Knight, J. L.; Kaus, J. W.; Cerutti, D. S.; Krilov, G.; Jorgensen, W. L.; Abel, R.; Friesner, R. A., OPLS3: A Force Field
646 Providing Broad Coverage of Drug-like Small Molecules and Proteins. *J. Chem. Theory Comput.* **2016**.
- 647 20. Humphrey, W.; Dalke, A.; Schulten, K., VMD: Visual molecular dynamics. *J. Mol. Graphics* **1996**, *14*, 33-38.
- 648 21. Sethi, A.; Eargle, J.; Black, A. A.; Luthey-Schulter, Z., Dynamical networks in tRNA:protein complexes. *Proc.*
649 *Natl. Acad. Sci.* **2009**, *106*, 6620.
- 650 22. Glykos, N. M., Software news and updates carma: A molecular dynamics analysis program. *J. Comput.*
651 *Chem.* **2006**, *27*, 1765-1768.
- 652 23. Eargle, J.; Luthey-Schulter, Z., NetworkView: 3D display and analysis of protein-RNA interaction networks.
653 *Bioinformatics* **2012**, *28*, 3000-3001.
- 654 24. Bhattacharyya, M.; Bhat, C. R.; Vishveshwara, S., An Automated Approach to Network Features of Protein
655 Structure Ensembles. *Protein Sci.* **2013**, *22*, 1399-1416.
- 656 25. Gadiyaram, V.; Vishveshwara, S.; Vishveshwara, S., From Quantum Chemistry to Networks in Biology: A
657 Graph Spectral Approach to Protein Structure Analyses. *J. Chem. Inf. Model.* **2019**, *59*, 1715-1727.
- 658 26. Stolzenberg, S.; Michino, M.; LeVine, M. V.; Weinstein, H.; Shi, L., Computational Approaches to Detect
659 Allosteric Pathways in Transmembrane Molecular Machines. *Biochim. Biophys. Acta, Biomembr.* **2016**, *1858*, 1652-
660 1662.
- 661 27. Schneider, S.; Provasi, D.; Filizola, M., How Oliceridine (TRV-130) Binds and Stabilizes a μ -Opioid Receptor
662 Conformational State That Selectively Triggers G Protein Signaling Pathways. *Biochemistry* **2016**, *55*, 6456-6466.
- 663 28. Jiang, Y.; Yuan, Y.; Zhang, X.; Liang, T.; Guo, Y.; Li, M.; Pu, X., Use of Network Model to Explore Dynamic
664 and Allosteric Properties of Three GPCR Homodimers. *RSC Adv.* **2016**, *6*, 106327-106339.
- 665 29. Genheden, S.; Ryde, U., The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities.
666 *Expert Opin. Drug Discovery* **2015**, *10*, 449-461.
- 667 30. Li, J.; Abel, R.; Zhu, K.; Cao, Y.; Zhao, S.; Friesner, R. A., The VSGB 2.0 model: A next generation energy
668 model for high resolution protein structure modeling. *Proteins: Struct., Funct., Bioinf.* **2011**, *79*, 2794-2812.
- 669 31. Flock, T.; Ravarani, C. N. J.; Sun, D.; Venkatakrishnan, A. J.; Kayikci, M.; Tate, C. G.; Veprintsev, D. B.; Babu,
670 M. M., Universal allosteric mechanism for G α activation by GPCRs. *Nature* **2015**, *524*, 173-179.
- 671 32. Marin, E. P.; Krishna, A. G.; Archambault, V.; Simuni, E.; Fu, W.-Y.; Sakmar, T. P., The Function of
672 Interdomain Interactions in Controlling Nucleotide Exchange Rates in Transducin. *J. Biol. Chem.* **2001**, *276*, 23873-
673 23880.
- 674 33. Zhou, Q.; Yang, D.; Wu, M.; Guo, Y.; Guo, W.; Zhong, L.; Cai, X.; Dai, A.; Jang, W.; Shakhnovich, E. I.; Liu, Z.-
675 J.; Stevens, R. C.; Lambert, N. A.; Babu, M. M.; Wang, M.-W.; Zhao, S., Common activation mechanism of class A
676 GPCRs. *eLife* **2019**, *8*, e50279.
- 677 34. Goetz, A.; Lanig, H.; Gmeiner, P.; Clark, T., Molecular Dynamics Simulations of the Effect of the G-Protein
678 and Diffusible Ligands on the $\beta 2$ -Adrenergic Receptor. *J. Mol. Biol.* **2011**, *414*, 611-623.
- 679 35. Liu, X.; Xu, X.; Hilger, D.; Aschauer, P.; Tiemann, J. K. S.; Du, Y.; Liu, H.; Hirata, K.; Sun, X.; Guixà-González,
680 R.; Mathiesen, J. M.; Hildebrand, P. W.; Kobilka, B. K., Structural Insights into the Process of GPCR-G Protein
681 Complex Formation. *Cell* **2019**, *177*, 1243-1251.e12.

- 682 36. Iiri, T.; Farfel, Z.; Bourne, H. R., G-protein diseases furnish a model for the turn-on switch. *Nature* **1998**,
683 *394*, 35-38.
- 684 37. Rondard, P.; Iiri, T.; Srinivasan, S.; Meng, E.; Fujita, T.; Bourne, H. R., Mutant G protein α subunit activated
685 by G β γ : A model for receptor activation? *Proc. Natl. Acad. Sci.* **2001**, *98*, 6150-6155.
- 686 38. Cherfils, J.; Chabre, M., Activation of G-protein G α subunits by receptors through G α -G β and G α -G γ
687 interactions. *Trends Biochem. Sci.* **2003**, *28*, 13-17.
- 688 39. Louet, M.; Martinez, J.; Floquet, N., GDP Release Preferentially Occurs on the Phosphate Side in
689 Heterotrimeric G-proteins. *PLoS Comput. Biol.* **2012**, *8*, e1002595.
- 690 40. Natochin, M.; Moussaif, M.; Artemyev, N. O., Probing the mechanism of rhodopsin-catalyzed transducin
691 activation. *J. Neurochem.* **2001**, *77*, 202-210.


692

693

694

695 **Table of Contents graphics**

696



697